Physiogenex will be presenting the effects of SARS-CoV-2 infection on dyslipidemia and NASH in its obese hamster model at Vascular Discovery 2022, to be held in Seattle, WA, USA on May12th-14th.
The oral abstract#112 entitled “Sars-CoV-2 Infection Promotes Dyslipidemia and Non-alcoholic Steatohepatitis In Diet-induced Obese Golden Syrian Hamsters” will be presented by Dr. François Briand, Director of Research and Business Development, on Thursday May the 12th, from 11:25am-11:40am during the oral presentations session dedicated to COVID-19.
Feel free to contact us if you wish to set-up an appointment with our oral abstract presenter Dr. François Briand, and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.